Reata (RETA) confirms submission of an NDA seeking approval for omaveloxolone to the FDA in the first quarter of 2022, following the completion of its... Find out more at https://ift.tt/2YhcWK3 via Entrepreneur.com

Read more of this post


This free site is ad-supported. Learn more